HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 23, 2024 10:30 ET
|
HiberCell, Inc.
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce...
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
October 07, 2024 07:00 ET
|
Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
Qubit Pharmaceuticals nominated for "Best start-up" award at Prix Galien USA 2024
August 19, 2024 11:00 ET
|
Qubit Pharmaceuticals
Press Release Qubit Pharmaceuticals nominated for "Best start-up" award at Prix Galien USA 2024 - Qubit Pharmaceuticals has been nominated for the 2024 edition of the prestigious Prix Galien USA, in...
Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum
June 06, 2024 03:00 ET
|
Qubit Pharmaceuticals
Press release Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum Qubit Pharmaceuticals joins the prestigious community of 100 disruptive...
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
May 28, 2024 08:00 ET
|
HiberCell, Inc.
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
April 05, 2024 10:00 ET
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
March 27, 2024 08:00 ET
|
Vector Pharma FZCO; Oncopeptides AB
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies
January 30, 2024 02:30 ET
|
Qubit Pharmaceuticals
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer...
PR : Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery
January 08, 2024 02:00 ET
|
ULYSSE COMMUNICATION
Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery Paris, France, 8 January, 2023 – Iktos, a company specialized in Artificial...
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology
December 05, 2023 12:26 ET
|
Syapse
Research collaboration between Syapse and the FDA Oncology Center of Excellence extended to assess fit-for-purpose RWD and explore the potential of RWE.